Stryker Co. (NYSE:SYK) Shares Sold by Legacy Private Trust Co.

Legacy Private Trust Co. trimmed its holdings in Stryker Co. (NYSE:SYK) by 4.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,542 shares of the medical technology company’s stock after selling 75 shares during the period. Legacy Private Trust Co.’s holdings in Stryker were worth $557,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Dynamic Advisor Solutions LLC raised its position in shares of Stryker by 2.3% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock valued at $1,080,000 after purchasing an additional 67 shares in the last quarter. Blue Zone Wealth Advisors LLC increased its holdings in shares of Stryker by 3.1% in the 3rd quarter. Blue Zone Wealth Advisors LLC now owns 20,669 shares of the medical technology company’s stock valued at $7,467,000 after acquiring an additional 627 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Stryker by 11.3% in the 3rd quarter. Versant Capital Management Inc now owns 962 shares of the medical technology company’s stock valued at $348,000 after acquiring an additional 98 shares during the last quarter. Bath Savings Trust Co increased its holdings in shares of Stryker by 0.4% in the 3rd quarter. Bath Savings Trust Co now owns 112,589 shares of the medical technology company’s stock valued at $40,674,000 after acquiring an additional 423 shares during the last quarter. Finally, Stokes Capital Advisors LLC increased its holdings in shares of Stryker by 1.4% in the 3rd quarter. Stokes Capital Advisors LLC now owns 27,289 shares of the medical technology company’s stock valued at $9,858,000 after acquiring an additional 389 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Up 1.6 %

Shares of NYSE SYK opened at $350.81 on Wednesday. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $374.63. The company has a market cap of $133.64 billion, a price-to-earnings ratio of 40.05, a P/E/G ratio of 2.71 and a beta of 0.91. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $350.01 and a 200-day simple moving average of $342.93.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the prior year, the business posted $2.54 earnings per share. Stryker’s revenue was up 8.5% compared to the same quarter last year. Sell-side analysts predict that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.91%. The ex-dividend date is Monday, September 30th. Stryker’s payout ratio is 36.53%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Evercore ISI boosted their price target on Stryker from $365.00 to $380.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Wolfe Research assumed coverage on Stryker in a research note on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $386.00 price objective on shares of Stryker in a research note on Wednesday, July 31st. Piper Sandler restated an “overweight” rating and set a $380.00 price objective on shares of Stryker in a research note on Tuesday, September 10th. Finally, BTIG Research upped their price objective on Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $379.37.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 220,068 shares of company stock valued at $71,811,372. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.